Compare Healios KK with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 46,711 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.71
-45.58%
9.55
Revenue and Profits:
Net Sales:
25 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,917 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.44%
0%
-11.44%
6 Months
-27.92%
0%
-27.92%
1 Year
9.9%
0%
9.9%
2 Years
114.84%
0%
114.84%
3 Years
12.5%
0%
12.5%
4 Years
-57.63%
0%
-57.63%
5 Years
-79.04%
0%
-79.04%
Healios KK for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
30.96%
EBIT Growth (5y)
3.53%
EBIT to Interest (avg)
-4.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.69
Sales to Capital Employed (avg)
0.06
Tax Ratio
5.82%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
11.57
EV to EBIT
-15.60
EV to EBITDA
-16.97
EV to Capital Employed
37.99
EV to Sales
510.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-243.59%
ROE (Latest)
-45.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
25.00
19.00
31.58%
Operating Profit (PBDIT) excl Other Income
-939.00
-696.00
-34.91%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,917.00
562.00
241.10%
Operating Profit Margin (Excl OI)
-40,440.00%
-40,210.50%
-22.95%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 31.58% vs -13.64% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 241.10% vs 126.19% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
104.00
560.00
-81.43%
Operating Profit (PBDIT) excl Other Income
-3,128.00
-2,605.00
-20.08%
Interest
76.00
142.00
-46.48%
Exceptional Items
442.00
-1,296.00
134.10%
Consolidate Net Profit
-2,229.00
-4,227.00
47.27%
Operating Profit Margin (Excl OI)
-32,721.20%
-5,182.10%
-2,753.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -81.43% vs 362.81% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 47.27% vs -10.86% in Dec 2024
About Healios KK 
Healios KK
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






